CONSOLIDATION TREATMENT OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A PROSPECTIVE, RANDOMIZED TRIAL COMPARING ALLOGENEIC VERSUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND TESTING THE IMPACT OF RECOMBINANT INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
CONSOLIDATION TREATMENT OF ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - A PROSPECTIVE, RANDOMIZED TRIAL COMPARING ALLOGENEIC VERSUS AUTOLOGOUS BONE-MARROW TRANSPLANTATION AND TESTING THE IMPACT OF RECOMBINANT INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
复制标题
DOI：
10.1182/blood.v86.4.1619.bloodjournal8641619
复制
发表时间：
1995-08-15
期刊：
影响因子：
20.3
通讯作者：
REIFFERS, J
中科院分区：
文献类型：
--
作者：
ATTAL, M;BLAISE, D;REIFFERS, J
在成人急性淋巴细胞白血病（ALL）中启动了一项前瞻性随机试验，以比较（1）异基因或自体骨髓移植（BMT）后的无病生存期（DFS）和（2）自体BMT后接受或不接受白细胞介素-2（IL-2）治疗的患者的复发率。共有135名年龄在55岁以下的既往未接受过治疗的患者接受了柏林-法兰克福-穆斯特（BFM）诱导方案：126名患者（93%）达到完全缓解（CR），其中120名为HLA分型。根据这种遗传随机化，具有（n = 43）或不具有HLA相同同胞（n = 77）的患者分别接受同种异体或自体BMT。HLA相合同胞组CR后3年DFS的概率显著高于HLA不相合同胞组（68% vs26%; P
A prospective, randomized trial was initiated in adult acute lymphoblastic leukemia (ALL) to compare (1) disease-free survival (DFS) after allogeneic or autologous bone marrow transplantation (BMT) and (2) the relapse rate of patients treated with or without interleukin-2 (IL-2) after autologous BMT. A total of 135 previously untreated patients, aged under 55 years, received the Berlin-Frankfurt-Muster (BFM) induction regimen: 126 patients (93%), of which 120 were HLA-typed, achieved complete remission (CR). According to this genetic randomization, patients with (n = 43) or without an HLA-identical sibling (n = 77) were to receive allogeneic or autologous BMT, respectively. The 3-year post-CR probability of DFS was significantly higher in the HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; P